Gilead Sciences, Inc. GILD
Verdict: Sell. Fair value $101 against a price of $118 on 6 Jan 2026, 15% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Net Income collapsed from $5.67B in 2023 to just $0.48B in 2024, a 91.5% decline. This was driven.... The massive divergence between Operating Cash Flow ($10.83B) and Net Income ($0.48B) in 2024....
Main risks
- Profitability Collapse: Net Income for 2024 plummeted to $0.48B from $5.67B in 2023, resulting in a near-zero Net Margin (1.7%) and ROE (2.5%), indicating a severe issue with GAAP profitability.
- Negative Incremental Returns on Capital (ROIIC): The calculated 3-year ROIIC is approximately -69%, suggesting that capital invested over the last three years has been value-destructive on an EBIT basis.
- Stagnant Revenue and High Leverage: Revenue growth is anemic (1.7% 3-yr CAGR), while the balance sheet is leveraged with a Debt/Equity ratio of 1.38. This combination increases financial risk if profitability does not recover.
- Net Income collapsed from $5.67B in 2023 to just $0.48B in 2024, a 91.5% decline. This was driven...
- The massive divergence between Operating Cash Flow ($10.83B) and Net Income ($0.48B) in 2024...
- Intense competitive environment